These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 8106629)

  • 1. Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors.
    Greenman Y; Melmed S
    J Clin Endocrinol Metab; 1994 Feb; 78(2):398-403. PubMed ID: 8106629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of somatostatin receptors on human pituitary adenomas in vivo and ex vivo.
    Nielsen S; Mellemkjaer S; Rasmussen LM; Ledet T; Olsen N; Bojsen-Møller M; Astrup J; Weeke J; Jørgensen JO
    J Endocrinol Invest; 2001 Jun; 24(6):430-7. PubMed ID: 11434667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatostatin receptor subtype gene expression in pituitary adenomas.
    Miller GM; Alexander JM; Bikkal HA; Katznelson L; Zervas NT; Klibanski A
    J Clin Endocrinol Metab; 1995 Apr; 80(4):1386-92. PubMed ID: 7714115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment.
    Horiguchi K; Yamada M; Umezawa R; Satoh T; Hashimoto K; Tosaka M; Yamada S; Mori M
    Endocr J; 2007 Jun; 54(3):371-8. PubMed ID: 17420609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does the response of GH-secreting pituitary adenomas to octreotide depend on the cellular localization of the somatostatin receptor subtypes SSTR2 and SSTR5?
    Pisarek H; Pawlikowski M; Kunert-Radek J; Winczyk K
    Endokrynol Pol; 2010; 61(2):178-81. PubMed ID: 20464704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
    Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
    J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization.
    Reubi JC; Schaer JC; Waser B; Mengod G
    Cancer Res; 1994 Jul; 54(13):3455-9. PubMed ID: 8012966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of somatostatin receptor (SSTR) subtypes in pituitary adenomas: quantitative analysis of SSTR2 mRNA by reverse transcription-polymerase chain reaction.
    Murabe H; Shimatsu A; Ihara C; Mizuta H; Nakamura Y; Nagata I; Kikuchi H; Nakao K
    J Neuroendocrinol; 1996 Aug; 8(8):605-10. PubMed ID: 8866248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage.
    Greenman Y; Melmed S
    J Clin Endocrinol Metab; 1994 Sep; 79(3):724-9. PubMed ID: 7521350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.
    Shimon I; Yan X; Taylor JE; Weiss MH; Culler MD; Melmed S
    J Clin Invest; 1997 Nov; 100(9):2386-92. PubMed ID: 9410919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors.
    Panetta R; Patel YC
    Life Sci; 1995; 56(5):333-42. PubMed ID: 7530798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas.
    Jaquet P; Ouafik L; Saveanu A; Gunz G; Fina F; Dufour H; Culler MD; Moreau JP; Enjalbert A
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3268-76. PubMed ID: 10487698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors.
    Kubota A; Yamada Y; Kagimoto S; Shimatsu A; Imamura M; Tsuda K; Imura H; Seino S; Seino Y
    J Clin Invest; 1994 Mar; 93(3):1321-5. PubMed ID: 8132773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene transcription of receptors for growth hormone-releasing peptide and somatostatin in human pituitary adenomas.
    Nielsen S; Mellemkjaer S; Rasmussen LM; Ledet T; Astrup J; Weeke J; Jørgensen JO
    J Clin Endocrinol Metab; 1998 Aug; 83(8):2997-3000. PubMed ID: 9709982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas.
    Taboada GF; Luque RM; Bastos W; Guimarães RF; Marcondes JB; Chimelli LM; Fontes R; Mata PJ; Filho PN; Carvalho DP; Kineman RD; Gadelha MR
    Eur J Endocrinol; 2007 Jan; 156(1):65-74. PubMed ID: 17218727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatostatin receptors in pituitary and development of somatostatin receptor subtype-selective analogs.
    Shimon I
    Endocrine; 2003 Apr; 20(3):265-9. PubMed ID: 12721506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion.
    Zatelli MC; Piccin D; Tagliati F; Ambrosio MR; Margutti A; Padovani R; Scanarini M; Culler MD; degli Uberti EC
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2797-802. PubMed ID: 12788890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of selective somatostatin analogs and cortistatin on cell viability in cultured human non-functioning pituitary adenomas.
    Padova H; Rubinfeld H; Hadani M; Cohen ZR; Nass D; Taylor JE; Culler MD; Shimon I
    Mol Cell Endocrinol; 2008 May; 286(1-2):214-8. PubMed ID: 18276067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors.
    Korbonits M; Jacobs RA; Aylwin SJ; Burrin JM; Dahia PL; Monson JP; Honegger J; Fahlbush R; Trainer PJ; Chew SL; Besser GM; Grossman AB
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3624-30. PubMed ID: 9768675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Importance of Somatostatin Receptor 2 (SSTR2) and Somatostatin Receptor 5 (SSTR5) Expression in Thyrotropin-Producing Pituitary Adenoma (TSHoma).
    Yu B; Zhang Z; Song H; Chi Y; Shi C; Xu M
    Med Sci Monit; 2017 Apr; 23():1947-1955. PubMed ID: 28434012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.